Benefits
Red Blood Cell Formation and Anemia Prevention
B12 is critical for red blood cell (RBC) production and DNA synthesis. Supplementation corrects megaloblastic anemia in B12-deficient individuals by supporting proper RBC maturation, reducing symptoms like fatigue, weakness, and pallor. Studies show that doses of 1,000 µg/day (oral or injectable) rapidly improve hematological parameters in pernicious anemia or dietary deficiency.
Neurological Health
B12 maintains myelin sheath integrity and supports nerve function. Supplementation can reverse neurological symptoms (e.g., numbness, tingling, cognitive issues) in deficient individuals and may reduce homocysteine levels, a risk factor for neurodegenerative diseases. A 2024 trial in Brazil suggested B12 reduces CCL11 expression in long COVID patients with visuoconstructive deficits, indicating potential neuroprotective effects.
Cardiovascular Health
B12 lowers homocysteine levels, which are linked to cardiovascular disease (CVD). Trials (e.g., a 2010 study in Turkey) show B12 supplementation improves coronary flow reserve in deficient elderly individuals, potentially reducing CVD risk. However, benefits are less clear in non-deficient populations.
Energy Metabolism
B12 supports energy production by aiding in the metabolism of fats and carbohydrates. Supplementation may alleviate fatigue in deficient individuals, though evidence for energy enhancement in healthy people is limited.
Pregnancy and Fetal Development
Adequate B12 supports fetal brain and nervous system development. Trials in Nepal and India (2020–2024) indicate supplementation in deficient pregnant women may reduce preterm birth risk and improve infant metabolic markers, though neurodevelopmental benefits are inconsistent.
Mental Health and Cognitive Function
B12 deficiency is linked to depression and cognitive decline. Supplementation may improve mood and cognitive symptoms in deficient individuals, but RCTs (e.g., Hong Kong 2016 trial) found no significant cognitive benefit in non-deficient older adults with mild deficiency.
Bone Health
Some studies suggest B12, by lowering homocysteine, may support bone health indirectly. However, the B-PROOF trial (2015) found no significant impact on physical performance or fracture risk in older adults.
Mechanism of action
Red Blood Cell Formation and DNA Synthesis
B12 acts as a cofactor for methionine synthase, an enzyme in the folate cycle that converts 5-methyltetrahydrofolate to tetrahydrofolate, enabling DNA and RNA synthesis. This is essential for erythropoiesis (red blood cell production). In B12 deficiency, folate is trapped as 5-methyltetrahydrofolate, impairing DNA synthesis and leading to megaloblastic anemia (large, immature red blood cells). Supplementation (e.g., 1,000 µg/day oral or injectable) restores methionine synthase activity, normalizing cell division and correcting anemia.
Neurological Function and Myelin Maintenance
B12 is a cofactor for methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA in the mitochondria, a step in fatty acid and energy metabolism. This supports myelin sheath formation, crucial for nerve insulation and signal transmission. Deficiency leads to methylmalonic acid (MMA) accumulation, disrupting myelin synthesis and causing neurological symptoms (e.g., neuropathy, cognitive impairment). Supplementation reduces MMA and homocysteine levels, restoring nerve function and potentially preventing demyelination. A 2024 trial showed B12 reduces CCL11 expression in long COVID via methyl-dependent epigenetic mechanisms, aiding visuoconstructive function.
Homocysteine Metabolism and Cardiovascular Health
B12 facilitates the conversion of homocysteine to methionine via methionine synthase, reducing homocysteine levels, a risk factor for cardiovascular disease (CVD). Elevated homocysteine damages vascular endothelium and promotes thrombosis. Supplementation (e.g., 500 µg/day with folate) lowers homocysteine, improving coronary flow reserve (as seen in a 2010 Turkish trial) and potentially reducing CVD risk in deficient individuals.
Energy Metabolism
Through its role in methylmalonyl-CoA mutase, B12 supports the citric acid cycle by producing succinyl-CoA, a key intermediate for ATP production. This enhances energy metabolism in cells, alleviating fatigue in deficient individuals by ensuring efficient fat and carbohydrate breakdown.
Fetal Development
B12 supports DNA synthesis and methylation reactions critical for fetal growth and neural tube development. Supplementation in deficient pregnant women ensures adequate methyl group availability for epigenetic regulation, potentially reducing preterm birth risk (as seen in 2024 Nepal and India trials).
Clinical trials
Double-blind, placebo-controlled RCT by London School of Hygiene & Tropical Medicine in 201 older adults examining B12 supplementation effects on cognition. (Eussen et al. 2006)
201 older adults.
Modest improvements on certain cognitive measures in B12-deficient subgroup. Note: B12 deficiency is common in elderly (~10-20%) due to atrophic gastritis reducing intrinsic factor; PROTON PUMP INHIBITORS and METFORMIN both impair B12 absorption — long-term users at risk.
27-month RCT in Hong Kong in 271 diabetic outpatients aged ≥70 with mild B12 deficiency receiving B12 vs placebo.
271 elderly diabetic patients.
B12 supplementation improved cognitive function and peripheral neuropathy markers vs placebo. Note: METFORMIN is a major risk factor for B12 deficiency — chronic users should have annual B12 status checked. ADA guidelines now recognize this.
Population-based, double-blind RCT in Nepal in 600 infants at risk of B12 deficiency. (Strand et al. 2020, PLoS Med)
600 infants in Nepal.
B12 supplementation improved neurodevelopmental scores in B12-deficient infants. Note: developing world B12 deficiency contributes to neurodevelopmental delays; addressing maternal/infant B12 status is critical public health intervention.
RCT in three centers in Pakistan (April-July 2024) in healthy adults with B12 deficiency comparing oral Sucrosomial® B12 vs intramuscular cyanocobalamin.
Adults with B12 deficiency.
Oral Sucrosomial® B12 produced comparable plasma B12 elevation to IM cyanocobalamin in the studied population. Industry-funded but important: high-dose ORAL B12 (1,000-2,000 µg/day) can effectively treat most cases of B12 deficiency without injections — well-established but underrecognized clinically.
Double-blind RCT (B-PROOF) in Netherlands in 2,919 adults aged ≥65 with elevated homocysteine receiving 2 years of B12 + folate supplementation.
2,919 elderly with elevated homocysteine.
PRIMARY ENDPOINT NEGATIVE: B12 + folate did NOT reduce fracture risk vs placebo. Important rigorous negative trial — homocysteine reduction does NOT translate to fracture prevention. Pattern of homocysteine reduction trials being negative for hard outcomes (similar VISP and HOPE-2 negative for stroke).
Placebo-controlled trial in 39 elderly subjects identified through community screening with low serum B12 receiving supplementation.
39 elderly with low B12.
B12 supplementation modestly improved cognitive measures in the deficient population. Older trial; modest sample.
Longitudinal cohort study in Brazil in patients with persistent visuoconstructive deficit (VCD) 10-16 months post-COVID. (2024)
Long-COVID patients with VCD.
B12 supplementation modulated peripheral blood biomarkers. CRITICAL CAVEAT: observational/cohort design, not RCT. Long-COVID is heterogeneous; supplement claims for long-COVID should be tempered.
Clinical trial in Turkey in elderly subjects with low serum B12 receiving folic acid + B12 supplementation. Outcomes: coronary flow reserve.
Elderly with low B12.
Modest improvements in coronary flow reserve. Note: HOPE-2 (large RCT) showed homocysteine reduction with B-vitamins did NOT reduce CV events overall.
2016 RCT in children with ASD testing methylcobalamin (B12) injections (75 µg/kg every 3 days).
Children with ASD.
Modest improvements in ASD behavioral measures. Note: ASD treatment landscape primarily uses behavioral interventions (ABA, speech therapy, OT); methyl-B12 has emerging but limited evidence; individual MTHFR variants may modulate response.
2010 pilot RCT in 30 children with autism testing methylcobalamin injections (64.5 µg/kg every 3 days for 8 weeks).
30 children with ASD (small).
Modest improvements in behavioral and biomarker measures in subset of responders. Pilot only.